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ABSTRACT
Renee E. Breaux: The Neuroprotective Effects of Estradiol and Genistein in Zebra Finch
Cerebellum
(Under the Direction of Dr. Lainy B. Day)

The estradiol (E2) synthetic pathway converts testosterone to E2 via aromatase (AROM)
and plays an important role in neuroplasticity. However, exogenous E2 increases cancer risk and
interferes with gonadal function. Phytoestrogens, plant-based estrogens, may provide
neuroprotection without negative E2 effects. Genistein (GEN), a soy phytoestrogen,
preferentially binds to estrogen receptor beta (ER β), which is expressed at a relatively higher
concentration than ER α in the cerebellum (CB). The songbird CB is an ideal model for
steroid-mediated plasticity. Songbird brains are highly plastic and CB contains all
steroid-synthetic enzymes. Previous studies in zebra finches (ZF) have shown that AROM and E 2
prevent post-injury secondary neurodegeneration. In our lab, we implanted adult male ZF with
either E2, GEN, or silastic vehicle (CON) and injected either saline (S) or an AROM inhibitor,
letrozole (LET) during delivery of cerebellar puncture lesions to test hormonal effects on testes
morphology, body weight, and neuroprotection. We previously reported that E2, compared to
GEN and control birds, had reduced testis mass, spermatozoa number, and laminarity. We also
found that body mass, which often decreases in birds over the course of invasive experiments,
decreased in E2 and control birds but not GEN birds. This suggests GEN may influence fat
metabolism as has been previously shown. In the present study, I determined the extent of
neuroprotection by measuring the volume of the lesion as a consequence of secondary
degeneration as labeled by Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling
(TUNEL) for each group. We expected that subjects given an injection of E2 + S and GEN + S
would have the smallest lesion volume, as the E2 and GEN should provide neuroprotection. We
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expected that the size of the lesion would be somewhat increased in subjects given E2 + LET and
GEN + LET, as the implanted E2 and GEN could counter local inhibition of AROM. We
expected that subjects given CON + S would have the second largest lesion volume, as there is
no additional E2 or GEN to contribute to neuroprotection. Finally, we expected that subjects
given CON + LET would have the largest lesion volume, as LET blocks the production of E 2 by
AROM and no additional E2 or GEN is present. Having measured 3-4 subjects per group, we did
not detect a significant impact of local or systemic treatments on secondary degeneration. There
was considerable individual variation within some groups that could be due to variation in
circulating hormone levels that will be measured by high-performance liquid chromatography
(HPLC) in the future. Power analyses indicate low power and the need for 18 additional subjects
or 3 per group, which we have ready to be measured. Furthermore, we have performed a
secondary assay that labels necrotic cells with Fluro-Jade (FJ) and measuring of lesion volumes
in this complementary assay should help to refine our conclusions.
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Introduction
Steroidal pathways are involved in neuroprotection in the brain. Within one particular
pathway, the enzyme AROM converts testosterone into the steroid E 2 (Azcoitia et al., 2010;
Duncan et al., 2013; Duncan & Saldanha, 2020; Mirzatoni et al., 2010; Peterson et al., 2001;
Saldanha et al., 2005; Saldanha et al., 2009; Spence et al., 2009). Recently, researchers have
begun to link this steroid hormone to prevention of secondary degeneration following neural
injury in a songbird model, the zebra finch (Taeniopygia Guttata) (Azcoitia et al., 2010; Duncan
et al., 2013; Duncan & Saldanha, 2020; Mirzatoni et al., 2010; Peterson et al., 2001; Saldanha et
al., 2005; Saldanha et al., 2009; Spence et al., 2009). Similar to E2, the enzyme AROM is
associated with protective and reparative functions. In the CB, constitutive expression of AROM
is limited (Duncan & Saldanha, 2020; Saldanha et al., 2005; Saldanha et al., 2009). However,
similar to previous studies where researchers found AROM increased within the hippocampus of
birds and mammals following neural injury, an upregulation of AROM transcription and
translation occurs within reactive glial cells of the ZF entopallium and Bergman glial cells of the
CB in regions surrounding neural injury, leading to increased production of E2 (Azcoitia et al.,
2010; Duncan et al., 2013; Duncan & Saldanha, 2020; Mirzatoni et al., 2010; Peterson et al.,
2001; Saldanha et al., 2005; Saldanha et al., 2009; Spence et al., 2009). When an AROM
inhibitor is administered, the extent of secondary degeneration increases (Azcoitia et al., 2010;
Duncan et al., 2013; Duncan & Saldanha, 2020; Saldanha et al., 2005; Saldanha et al., 2009).
This suggests that E2 is neuroprotective because when AROM is inhibited from producing E2, the
extent of damage worsens. Songbirds, like the ZF, are a useful model to examine the
neuroprotective effects of E2 and AROM as they have greater steroidogenesis than non-songbirds
and many mammals (Brann et al., 2022) but low levels of AROM in CB (Azcoitia et al., 2010;
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Duncan et al., 2013; Duncan & Saldanha, 2020; Mirzatoni et al., 2010; Peterson et al., 2001;
Saldanha et al., 2005; Saldanha et al., 2009; Spence et al., 2009). While ZF AROM is
constitutively low in CB scattered in only a few Purkinje cells, AROM and all other
steroidogenic enzymes are produced in CB and several have been shown to be sensitive to neural
insult (Mirzatoni et al., 2010; Peterson et al., 2001; Spence et al., 2009). Furthermore, few
studies have linked upregulation of AROM or its inhibition with behavioral outcomes post-injury
as has been demonstrated in the CB of ZF (Spence et al., 2009). When an AROM inhibitor is
present, behavioral outcomes are imparied; and when E2 was added, injury related deficits
improved (Spence et al., 2009). Thus, the ZF CB is an ideal model for studying the effects of
estrogens and phytoestrogens on neuroprotection.
Neuroprotection occurs by impeding a variety of processes pre and post injury. The
processes of neuronal cell death occur in two distinct stages: primary degeneration and
secondary degeneration (Duncan et al., 2013; Duncan & Saldanha, 2020). During the process of
primary degeneration, cell death occurs at the direct site of contact with the source of injury.
Secondary degeneration then follows primary degeneration and affects the cells surrounding the
site of injury. This secondary degeneration results from the release of apoptotic signals by the
cells that die during primary degeneration and occurs via apoptosis or necrosis. While necrosis
occurs as a result of mechanical tissue damage, apoptosis occurs actively and requires the input
of energy. Within the brain, AROM and E 2 are thought to function to protect the neurons by
limiting these processes of apoptosis and secondary necrosis surrounding the site of injury.
While research shows that E2 plays a role in neuroprotection, its potential for negative
effects within the body complicate administration of E2 to prevent secondary degeneration. In
women E2 is known to increase the risk of of stroke and cancer when administered during
2

menopause (Jiang et al., 2013; Sites, 2008). In men E2 is associated with a decrease in male
reproductive functions (Halldin et al., 2005; Leavy et al., 2017; Rochester et al., 2010).
Phytoestrogens, plant-derived estrogenic compounds, may potentially serve as a replacement for
E2 to decrease the extent of neural degeneration at the site of injury while avoiding the negative
effects of E2 (Corbitt et al., 2007). Both the structure and function of phytoestrogens within the
brain are similar to that of E2. Specifically GEN, a type of phytoestrogen classified as an
isoflavone that is found in soy and fava beans, binds to estrogen receptors within the brain and
has been shown to have neuroprotective functions by decreasing apoptosis during secondary
degeneration in rodents (Corbitt et al., 2007; Jiang et al., 2013). While chronic administration of
GEN is associated with reproductive harm within males, decreasing sperm count and quality, it is
believed that acute administration of GEN will have few negative consequences on gonadal
function (Eustache et al., 2009). Within tissues, two distinct types of estrogen receptors exist:
estrogen receptor alpha (ER α) and estrogen beta (ER β) (Duncan & Saldanha, 2020). In the
reproductive system of male rats, E2 binds to both ER α and ER β (Ball et al., 2010). While GEN
binds to both ER α and ER β, it is more potent when binding to ER β (Katzenellenbogen &
Katzenellenbogen, 2000), the estrogen receptor more common in the ZF CB. The binding of E2
or GEN to an ER is what activates genes and proteins that function in neuroprotection, showing
that binding to an ER is essential for E2-related neuroprotection (Azcoitia et al., 2010; Duncan et
al., 2013; Duncan & Saldanha, 2020; Mirzatoni et al., 2010; Peterson et al., 2001; Saldanha et
al., 2005; Saldanha et al., 2009; Spence et al., 2009).
Our lab examined the role of GEN and E2 on male gonads and neuroprotection in zebra
finches by implanting E2 or GEN silastic hormones or silastic alone in addition to injecting LET
and S at the site of cerebellar lesions. Thus far, we have examined the detrimental effects of E2
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on the male reproductive system and the possible protective effects of GEN on testes mass,
sperm density, and laminarity (McFatridge, 2020). We found that E2 significantly reduced testes
mass relative to CON, while GEN maintained a mass that was not significantly different from
CON. With regards to spermatozoa production and laminarity, we found that only 5/9 birds that
received E2 produced spermatozoa and birds that received E2 experienced reduced sperm density
and laminarity, while birds treated with GEN and CON showed normal levels of each. Thus
GEN could serve as a replacement for E2 if it provides neuroprotection while diminishing
reproductive harm.
In our previous study, we found that GEN offered protection against the typical handling
related decreases in body mass that were seen in E2 and controls over the 15 days of the
experiment (McFatridge, 2020). This maintenance of body weight may be attributed to the
potential lipogenic effects of GEN. This ability to induce adipogenesis, however, is regulated by
transcription factors and is found to be dosage-dependent (Dang, Audinot, Papapoulos, Boutin &
Löwik, 2003). Specifically, GEN is known to bind to the peroxisome proliferator-activated
receptor-γ (PPARγ), causing an increase in adipogenesis (Dang et al., 2003). While estrogens
typically bind to ER α and β to induce lipolysis, the binding of GEN to PPARγ has
anti-estrogenic effects, reducing lipolysis and increasing adipogenesis (Dang et al., 2003; Penza
et al., 2006). The ability of GEN to induce adipogenesis, however, depends on the amount of
GEN present. In one study, researchers found that a high dosage of GEN is needed to have
anti-estrogenic effects and increase adipogenesis (Penza et al., 2006). While it is unclear with
regards to ZF what dosage of GEN will increase adipogenesis or how many PPARγ receptors are
present within the cerebellum, it is likely that the amount of GEN administered was high enough
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to activate PPARγ, increasing adipogenesis and protecting against experimental handling related
weight loss given our findings of weight maintenance in GEN implanted birds.
Ultimately, the purpose of my continuation of this study was to evaluate the
neuroprotective effects of E2, as well as to test the potential neuroprotective effects of GEN.
Based on previous studies, which suggest that E2 is neuroprotective, I hypothesized that groups
administered E2 will experience a decrease in the extent of secondary degeneration relative to the
CON. When LET is administered, I predicted that the extent of neurodegeneration would
increase, as there was a lack of E2 present due to the inhibition of AROM. Similarly to the effects
of E2, I expected that GEN would reduce the size of the lesion, providing neuroprotection. From
the results of this study, I hoped to determine if GEN could serve as a neuroprotective
replacement for E2.
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Materials/Methods
Subjects
Male ZF (36) were bred at the University of Mississippi (IACUC protocol 13-024). Birds
selected for this experiment were adults (6.5 months to 3 years old and weighing between 12 and
20.5 g. Following assignment to treatment groups, birds were housed 6 subjects per cage (L 40.6
cm, W 59.7 cm, H 40.6 cm). A 12 hour cycle of light and dark was maintained, and the
temperature and humidity were maintained at ~70°F and ~37% humidity. Seeds and water were
provided daily, along with egg and bread twice a week. A cuttle bone and perches were provided.

Materials
Rope implants made from medical grade silastic adhesive (Dow Corning, Auburn, MI) mixed
11:1 with ~500 μg of E2, as has previously been shown to raise E2 levels and provide
neuroprotection in ZF (Saldanha et al., 2005). GEN was given at 40:1 with ~1000 μg of GEN,
based on effective dosages and the weight of subjects in studies using mice and Japanese quail
(Penza et al., 2006; Viglietti-Panzica et al., 2007), as well as unpublished data from our lab on
the effects of three doses of GEN on behavior post-CB-lesion in ZF. There appear to be no
published studies using silastic implants of GEN in ZF, and almost all studies of GEN effects in
birds use dietary administration (Corbitt et al., 2007). Control implants contained silastic only
(CON). Silastic mixtures were extruded from a 5 mL luer lok syringe onto a glass slide, allowed
to dry, and sliced into 6 mm pieces weighing between 18.4 and 20.7 mg. They were matched to
bird weight as much as possible. Intracerebral injections contained either 50 micrograms of 1%
LET in saline or avian physiological saline (S).
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Methods
Implants and Injections
On day 0, 12 days prior to surgery, silastic ropes (E2, GEN, or silastic control) were implanted.
Each bird was provided brief isoflurane exposure for light anesthesia, and the rope was
implanted subcutaneously within the back of the neck according to the assigned group. Opsite
adhesive dressings were placed on top of the site of implantation, and implant adjustment and
additional adhesive was applied if the implant moved out of its original location.
On post-implant day 12, implantation, ZF were deprived of food for 2 hours prior to
surgery. Birds were anesthetized by injecting 15-20 μL of 1.5-2 mL/Kg equithesin IM into the
pectoral muscle. This was followed by concentrated isoflurane inhalant delivered from a 50 mL
conical tube until the birds were no longer reactive to plucking of feathers around the ears and
were no longer affected by the ear bars, which were covered with EMLA cream (2.5%
lidocaine/2.5% prilocaine, generic). A Kopf stereotax (Tujunga, CA) secured their beaks and
allowed accurate lesion placement. A small tube was placed on the bottom side of the Kopf beak
holder with only the ventral beak position modified to administer the isoflurane gas inhalant.
Anesthesia was maintained with oxygen to isoflurane gas at 1-2% during surgery. Held ventral
side down on a 37°C heating pad with circulating water, an injection of lidocaine/bupivacaine
local analgesic solution (2 mg/kg) was administered under the skin of the head. A craniotomy
was performed above the central sinus and CB and a unilateral puncture lesion (left and right
counterbalanced within groups) was placed with a 26-gauge needle at LM +/-0.7, RC -2.4 and
DV 4.5 relative to 0 set at the caudal aspect of the junction between the basilar artery and the
caudal ramus. The needle was held in place for one minute and then backed out halfway from the
lesion, and an intracerebral injection of 50-μg of 1% LET or S was administered within the
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lesion site. The skin was then replaced, and the area was covered with Opsite dressing (Smith &
Nephew, Memphis, TN) and the wound treated with neosporin + pain. Following surgery, the
birds were placed in an incubator at 32°C, and offered droplets of water at the corner of their
beaks after they began to ambulate. For two hours, the birds remained in isolation and were then
returned to mixed experimental bird cages after confirming a lack of stress behaviors. The
administration of the rope implant and intracerebral injection created six groups of subjects:
GEN + S, GEN + LET, E2 + S, E2 + LET, CON + S, or CON + LET.

Tissue Preparation and Staining Procedures
Seventy-two hours following surgery the subjects were euthanized. This time period was selected
based on previous studies, where researchers observed a maximal increase in AROM 72 hours
after surgery (Mirzatoni et al., 2010; Peterson et al., 2001; Wynne & Saldanha, 2004). The brain
of each bird was extracted, frozen on a dry ice acetone slurry, and stored at -80°C. Each brain
was cut at 30μ into 3 series using a cryostat, slices were mounted on electrostatic slides, and
stored at -80°C. The slides were then thawed for 30 minutes and baked in a 37 degree oven for
20 minutes. After baking, one series was used in a TUNEL assay and another was stained with
Fluoro-Jade (FJ). TUNEL detects DNA breakage that occurs during apoptosis by labeling the
exposed 3’-OH termini of DNA strands. TUNEL cells were labeled with VectorNovaRED HRP
substrate. The tissue was counterstained with methyl green, then allowed to air dry. A second
slide series was stained using FJ B, which identifies cells affected by secondary degeneration.
Each slide was rinsed with distilled water (DH2O), dehydrated using ethanol (EtOH), incubated
in 0.06% KMnO4, rinsed again in DH2O, incubated in 0.001% FJ B solution for 30 minutes with
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gentle shaking, then finally rinsed a third time with DH2O before coverslipping. The third series
of slides remains unstained.

Quantification of Neuroprotection
Lesion volume was measured using Stereologer software (Stereological Resource Center, St.
Petersburg, FL) to determine the extent of secondary degeneration. Analyzed images were taken
using an Imi Tech IMC-3145FT camera (Imi Tech, Seoul, South Korea) from a Zeiss light
microscope (Zeiss AxioImager M1, Germany). A single hemisphere of each cerebellum was
examined, as the lesion only appeared in one hemisphere. For most subjects, lesions were found
in 10-15 sections. With sampling intervals varying between 270-450 μm apart depending on the
length of the lesion from rostral to caudal to equate sampling density. Using 5x magnification,
each lesion was identified, a rough outline of the lesion was circled, and a grid of Cavalieri
points was placed over this outline. The points that overlapped with the lesion, including points
located within the lesion path but excluding regions without TUNEL reactivity, were selected.
The points on the grid represent an area of 15,000 µ2.
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Image 1: TUNEL-labeled lesion with grid of Cavalieri points
Then, at 100x oil magnification, the slice thickness was measured along the Z-axis by locating
the values at which the upper and lower aspects of the slice were focused. With this information,
the overall volume of each lesion was calculated using the formula V = 𝑇 ∙ Σ𝐴, where V is the
region volume estimate, T is the thickness, and A is the sum of areas from included points
(Mouton, 2011). The average coefficient error across all subjects, which accounts for variance
and variation between samples, was 3.7% (Mouton, 2011). This process has been performed on a
portion of the TUNEL-labeled subjects and will be performed on the FJ-labeled subjects in the
near future.
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Results
We used univariate two-way analysis of variance (ANOVA) with the Type III Sum of
Squares (SPSS 28, IBM Corp., Chicago) to compare differences between treatment groups. We
confirmed homogeneity of variance among groups via Levene’s Test (all ps>0.52) and
homoscedasticity of the error variance in our model via the F-Test (p=0.40). Residuals were
normally distributed based on Q-Q plots. One possible concern is that despite statistical tests that
ANOVA assumptions were met, the influence of injections and implants on secondary
degeneration is unlikely to be independent. Thus, we also ran analyses using one-way ANOVA
of our 6 groups, followed by post-hoc tests, as well as the nonparametric Kruskal-Wallis tests for
completeness. Given trends for preferences in non-frequentists statistical approaches, we also
examined equivalent Bayesian models and calculated effect sizes using JASP 16.1 (University of
Amsterdam) and projected sample sizes needed to detect group differences via G*Power 3.1.9.6
(UCLA).
Contrary to expectations, E2 and GEN treatment did not decrease secondary degeneration
((F2,14)=4.6, p=.18), nor did LET increase TUNEL labeled volume ((F1,14)=3.08, p=.22), with
no detectable interaction (F(2,14)=.24, p=.79). Effect sizes were very low (𝟂s from 0.00-0.01).
Significance of these effects and interpretation did not change using One-Way ANOVA or
nonparametric equivalents. Baysian analysis also supported the null model using JASP default
settings for posterior sample runs and prior distributions. The BF10 values in favor of the null
ranged from 0.32 to 0.61, and R2 0.05 (95% credibility interval 0-0.27) suggesting great
uncertainty about any effect size despite low error in the model for implant (0.02%) and injection
(0.002%) and high error for the interaction (0.88%) regardless of using auto vs. 100,000 sample
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run settings. Finally, G*Power analysis suggested a total of 18 subjects would be needed to
obtain significance at p=0.05 and power of 0.8 given effect sizes found for partial eta2.

Figure 1: Mean and range of TUNE-labeled lesion volume for each treatment.
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Figure 2: Model averaged posterior probability distributions for effects. The density is the
likelihood of the variable falling at points on the curve showing posterior means (x-axis),
and the lines above the curves are the 95% credibility range.
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Discussion
Drug treatments did not appear to have the expected effects on the extent of secondary
degeneration. Power analyses suggested that we need at least 18 more subjects (3/group) to
detect differences. Fortunately, this number of subjects has already been run in this experiment,
but the TUNEL reactive lesion volumes have not yet been measured for all subjects.
Understanding that differences were not statistically significant likely due to low sample
size, we nonetheless discuss herein the pattern of results we saw and interpret these results in
light of our hypotheses. As can be seen in Figure 1, relative to controls, the extent of
degeneration numerically trended in a direction suggesting that GEN decreased the extent of
secondary degeneration. In addition, a numerical trend was found that suggests that subjects
locally injected with LET had a greater extent of secondary degeneration relative to birds
injected with S (see Figure 1). Thus, acute, local AROM inhibition might prevent conversion of
testosterone to E2 and/or decrease reactive gliosis, ultimately leading to a decrease in
neuroprotection. Contrary to expectations, we observed that the results for subjects treated with
E2 implants trended in an unexpected direction. While not statistically significant, the data
collected so far for E2 subjects suggested increasing secondary degeneration surrounding lesions
similar to or greater than CON subjects, and possible reasons for this result will be discussed
below.
Researchers have previously suggested that GEN has neuroprotective effects by
decreasing apoptosis, inflammation, and antioxidants in rats following a stroke (Azcoitia et al.,
2010; Jiang et al., 2013). In this study, I similarly found the mean values of the extent of
degeneration in subjects that received a GEN implant trended in the direction that suggests GEN
offers some neuroprotection post-cerebellar lesion in ZF, although not statistically significant.
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These results were present in both subjects injected with S and those injected with LET. Acute
local AROM inhibition, therefore, may not interfere with the ability of GEN to prevent
secondary degeneration 3 days post-lesion.
In previous studies, researchers found that when AROM is inhibited, secondary
degeneration increases (Azcoitia et al., 2010; Duncan et al., 2013; Duncan & Saldanha, 2020;
Saldanha et al., 2005; Saldanha et al., 2009). Based on these studies and my own results from my
current study, one could assume that when AROM is inhibited and unable to convert testosterone
to E2, there is a lack of neuroprotection, suggesting the neuroprotective effects of
AROM-induced E2.
Compared to the effects of GEN and LET on secondary degeneration, the mean values of
secondary degeneration for subjects treated with E2, although not significant, trended in an
unexpected direction. Previous researchers have found that E2 decreases the extent of
degeneration following neural damage (Azcoitia et al., 2010; Duncan et al., 2013; Duncan &
Saldanha, 2020; Mirzatoni et al., 2010; Peterson et al., 2001; Saldanha et al., 2005; Saldanha et
al., 2009; Spence et al., 2009). It is possible that many factors may have contributed to this.
First, it is possible that our results strayed from what was expected due to different mechanisms
occurring within the cerebellum compared to studies in entopallium (Saldanha et al., 2005;
Wynne & Saldanha, 2004). Specifically, rather than E2, it is possible that AROM or other
steroids and/or synthetic precursors that are upregulated within the CB post-lesions (Mirzatoni et
al., 2010) provide neuroprotection. However, E2 related improvement of CB-lesion induced
deficits do not fit with this interpretation, unless behavioral improvements are not due to
neuroprotection. In addition, given that acute, local LET seems to inhibit local AROM from
upregulating E2 due to the increase in secondary degeneration relative to the CON, E2 may need
15

to be administered locally to compensate for the lack of local AROM. Using HPLC will allow us
to quantify the amount of circulating E2 and GEN in subjects to determine what amounts of E2
and GEN were actually present. Regardless of the effects of E2 on secondary degeneration, it is
clear that the amount of E2 present was sufficient to induce reproductive problems within our
subjects (McFatridge, 2020). Given that similar levels of E2 are also known to protect against
lesion induced behavioral deficits, it is possible that an increase in our sample size may support
these previous results (Spence et al., 2009) or provide clarity of CB E2 mechanisms related to
neuroplasticity.
Given that GEN seems to reduce the extent of secondary degeneration following injury
while decreasing negative consequences, such as reproductive issues, it is possible that GEN
may be used as a replacement for E2. Because previous studies have shown that E2 may protect
against secondary degeneration following neural damage, such as ischemic strokes, it is possible
that, as women approach menopause and experience a decrease in the amount of estrogen
circulating throughout their bodies, there would be an increase in damage following neural injury
(Duncan & Saldanha, 2020). Limitations exist, however, in the amount of estrogen
supplementation that the body can tolerate before additional complications, such as breast
cancer, can arise (Jiang et al., 2013; Katzenellenbogen & Katzenellenbogen, 2000; Sites, 2008).
Because cancer cells typically contain ER α, an increase in E2 supplementation which binds to
ER α would lead to this increase in cell proliferation, increasing cancer risk. In contrast, because
ER β is typically not found on cancer cells, the preferential binding of GEN to ER β would
diminish cancerous effects (Jiang et al., 2013). Therefore, our results thus far suggest the
possibility that GEN supplementation might be benificial for neuroprotection in menopausal
women while avoiding additional harmful effects that E2 could cause if added subjects continue
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the current trend. In addition, men may benefit from GEN as well. We and others have shown
that E2 leads to reproductive deficiencies, including a decrease in testis mass, spermatozoa
number, and laminarity (Halldin et al., 2005; Leavy et al., 2017; McFatridge, 2020; Rochester et
al., 2010). Therefore it is possible that the negative effects of taking an estrogen supplement
following a brain injury may outweigh the positives. Furthermore, we have found that GEN
maintains body mass throughout the course of an experiment, showing that it may have lipogenic
effects, which may be beneficial in humans during recovery from brain damage (McFatridge,
2020). However, similarly to how our results for E2 differed from previous studies, the potential
for different reactions to GEN supplements within the human brain compared to ZF CB still
remains, and further research will need to be conducted to test these reactions.
In order to fully interpret the neuroprotective effects of E2 and GEN in the ZF cerebellum
and make appropriate comparisons with human neurophysiology, we need to complete data
collection in the current study. Because we currently have low power, we plan to continue our
measurements of the extent of TUNEL reactive lesion volumes on at least 18 more subjects. We
know that some subjects lost implants prior to the end of the experiment, and our initial analyses
focused on only those subjects who completed the experiment with intact implants. Thus, it will
be crucial to quantify the amount of circulating E2 and GEN using HPLC to adjust for any
differences among individuals in these levels and to allow inclusion of subjects for which we
could not locate implants, but may have levels of circulating E2 or GEN suggesting influence of
these drugs at the time of blood sampling. We will also complete analyses of FJ-labeled slices to
determine the extent of apoptosis surrounding lesions. Thus far FJ-labeled lesions appear slightly
less extensive, but very similar in shape and size in the same individuals as the TUNEL reactive
regions. Our studies focusing on the extent of secondary damage to the lesioned brain,
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specifically in the CB, with its low constitutive AROM and E 2, offer a unique extension to
previous research. A handful of studies have shown upregulation of molecules in the
steroidogenic pathway or effects of AROM and E 2 manipulations on behavior post CB lesion
(Duncan & Saldanha, 2020; Mirzatoni et al., 2010; Spence et al., 2009). Yet, none of these
confirmed the effects of these changes on the damaged brain with regards to the extent of
secondary degeneration. Further, the vast majority of research in the area of AROM and E 2
effects have been in brain regions like the hippocampus that are regularly steroidogenic, blurring
the effects of neural reactivity to injury and normal steroidogenic effects (Saldanha et al., 2005;
Saldanha et al., 2009). Thus, our research offers an essential focus on whether these
steroidogenic pathways provide neuroprotection via local and systemic delivery and further
extend these studies into the possible protective effects of a readily available phytoestrogen that
might be administered as a subcutaneous implant or as a dietary supplement.
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